Purple Biotech Ltd (PPBT) - News Archive

Purple Biotech Celebrates Manufacturing Milestone for IM1240: A Tri-Specific Antibody from the CAPTN-3 Platform Purple Biotech, a leading biopharmaceutical company focused on developing innovative therapies for cancer t...

Purple Biotech s Groundbreaking Patent Intent and Phase 2 Study: A New Era in Cancer Treatment Recently, Purple Biotech announced the significant news of receiving an intention to grant a European patent that covers its...

In a significant development for the field of oncology, Purple Biotech Ltd, a pioneering company based in Rehovot, Israel, has revealed final data from its Phase 2 clinical study of CM24 in patients with pancreatic canc...

Rehovot, Israel, December 5, 2024 In a move that underscores its commitment to advancing innovative cancer therapies, Purple Biotech Ltd. (NASDAQ/TASE: PPBT) has successfully closed a registered direct offering for 472,...

: Purple Biotech Ltd. continues to make strides in the oncology space, specifically with its lead drug candidate, CM24, which is set to be discussed at the upcoming American Association for Cancer Research (AACR) Specia...

Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage biopharmaceutical company based in Rehovot, Israel, is making significant strides in oncology, with encouraging interim results from their Phase 2 pancreatic can...

Purple Biotech Ltd., a clinical-stage biopharmaceutical company focused on developing innovative oncology therapies, has recently announced additional positive interim results from its randomized Phase 2 study of CM24....

Purple Biotech Ltd. (NASDAQ/TASE: PPBT), renowned for pushing the boundaries of cancer treatment, has announced strikingly positive interim results from their ongoing Phase 2 study of CM24, a pioneering therapy for meta...

In an exciting advancement for pancreatic cancer therapeutics, Purple Biotech has been selected to present a late-breaking abstract poster at the prestigious American Society of Clinical Oncology (ASCO) 2024 Annual Meet...

Purple Biotech Advances NT219 in the Treatment of Head and Neck Cancer, Reaching Recommended Phase 2 DoseREHOVOT, Israel, Feb. 01, 2024 - Purple Biotech Ltd. (Purple Biotech or the Company) (NASDAQ/TASE: PPBT), a pionee...

Purple Biotech Announces $5 Million Registered Direct Offering: A Boost for Innovative Cancer TherapiesIn an exciting development, Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage biotech company focusing on no...